Most people treat allergy season like weather: something to endure, not something to fix. Antihistamines, nasal sprays, and eye drops get people through the worst weeks, but none of them touch the underlying immune response causing the reaction in the first place. Sublingual immunotherapy, often called allergy drops, has existed as an alternative for years. The problem was never whether it worked. It was access.
Traditional immunotherapy has typically meant either weekly allergy shots at a specialist’s office or a sublingual regimen still tied to in-person evaluation and monitoring. That model works fine for patients near a major city with a flexible schedule. It works far less well for everyone else, and allergists are not evenly distributed across the country.
Telehealth has started closing that gap by moving the entire process online: remote allergen testing, a formulation built around a patient’s specific triggers, and shipped doses a patient administers at home. A recent real-world study on this model, run through the telehealth platform Curex, tracked patients over time and found that adverse events were both infrequent and mild when they did occur, mostly localized itching or irritation rather than anything serious. That safety profile lines up with decades of prior immunotherapy research and adds evidence to something telehealth providers have argued for a while: allergen immunotherapy doesn’t need a weekly office visit to be administered responsibly.
That matters beyond allergy care specifically. Chronic conditions across the board, from dermatology to metabolic health, are shifting toward remote-first treatment models built on personalized formulations and digital monitoring rather than recurring in-person visits. Allergy treatment looks to be next in that shift, and the data needed to support it at scale is starting to arrive alongside the platforms making it possible.
For patients who have spent years choosing between a weekly commute to a specialist and just riding out the symptoms, that’s a meaningful third option finally backed by real numbers instead of just convenience.